Luyan Pharma Co (SZSE:002788) LT-Debt-to-Total-Asset : 0.06 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Luyan Pharma Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Luyan Pharma Co's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.06.

Luyan Pharma Co's long-term debt to total assets ratio declined from Mar. 2023 (0.06) to Mar. 2024 (0.06). It may suggest that Luyan Pharma Co is progressively becoming less dependent on debt to grow their business.

Luyan Pharma Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Luyan Pharma Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Luyan Pharma Co LT-Debt-to-Total-Asset Chart

Luyan Pharma Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.03

0.05

0.06

Luyan Pharma Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.06	0.06	0.06	0.06	0.06

Luyan Pharma Co LT-Debt-to-Total-Asset Calculation

Luyan Pharma Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	652.957	/	11793.594
	=	0.06

Luyan Pharma Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	665.075	/	12021.181
	=	0.06

Luyan Pharma Co (SZSE:002788) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Luyan Pharma Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Luyan Pharma Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Luyan Pharma Co (SZSE:002788) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Luyan Pharma Co Ltd (SZSE:002788) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

N/A

Address

1004 Ridge Road, Huli District, Fujian Province, Xiamen City, CHN, 361 010

Website

http://www.luyan.com.cn

Luyan Pharma Co Ltd, formerly Luyan (Fujian) Pharma Co Ltd engages in the production, operation, distribution, and retail of human health products in China. It provides medical and health products.

Executives

Zhu Ming Guo	Executives
Yang Cong Jin	Directors, executives
Lei Ming	Directors, executives
Li Wei Yang	Executives
Cai Mei Zhen	Supervisors
Li Cui Ping	Supervisors
Wu Jin Xiang	Directors, executives
Zhang Jun Ying	Executives
Wu Huo Lu	Director

Luyan Pharma Co (SZSE:002788) Headlines

No Headlines